Matell G
Myasthenia Gravis Center, Karolinska Institutet, South Hospital, Stockholm, Sweden.
Ann N Y Acad Sci. 1987;505:589-94. doi: 10.1111/j.1749-6632.1987.tb51327.x.
Azathioprine may be tried for treatment of severe myasthenia gravis, in a dose of 2 mg/kg BW. With careful monitoring the side reactions may be controlled. The therapeutic response will occur after a time delay of 4-8 months. About one-third of patients with type II MG (severe, late onset, HLA B8-) will proceed to a complete but azathioprine-dependent remission, and the remaining two-thirds to a marked improvement. In type I MG (early onset, HLA B8+) azathioprine is less effective but will help keep down the need for corticosteroids or plasmapheresis.
硫唑嘌呤可尝试用于治疗重症肌无力,剂量为2毫克/千克体重。通过仔细监测,副作用可以得到控制。治疗反应将在4至8个月的时间延迟后出现。约三分之一的II型重症肌无力患者(严重、迟发性、HLA B8阴性)将实现完全但依赖硫唑嘌呤的缓解,其余三分之二则会有明显改善。在I型重症肌无力患者(早发性、HLA B8阳性)中,硫唑嘌呤效果较差,但有助于减少对皮质类固醇或血浆置换的需求。